Rheumatoid Arthritis Drugs Market Size- By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Rheumatoid Arthritis Drugs Market Introduction and Overview

According to SPER market research, Rheumatoid Arthritis Drugs Market Size- By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033 state that the Global Rheumatoid Arthritis Drugs Market is predicted to reach 78718.42 million by 2033 with a CAGR of 3.8%.

Rheumatoid arthritis is an autoimmune disease that results in the body's immune system attacking its own tissues, including joints. This leads to edema and painful joint stiffness. A medication used to treat rheumatoid arthritis is known as an anti-rheumatic medication. All ages are affected by this ailment, albeit the elderly are most susceptible to it. Rheumatoid arthritis symptoms include swelling, stiffness, pain, and discomfort in the joints. Rheumatoid arthritis currently has no recognized treatment.

On January 30, 2020, the World Health Organization (WHO) deemed the COVID-19 pandemic a global public health emergency. Globally, COVID-19 has had an impact on around 210 countries. Patients with rheumatoid arthritis who also have COVID-19 infection may be more likely to experience severe symptoms and other problems, according to the Lancet Rheumatology 2020. Certain DMARDs, such hydroxychloroquine, are being studied as possible COVID-19 therapies in addition to being often used to treat rheumatoid arthritis.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered AbbVie Inc, Johnson & Johnson Innovative Medicine, Amgen Inc, Pfizer Inc, Novartis AG, Sanofi S.A, F. Hoffmann-La Roche Ltd, Merck & Co, Inc, Bristol-Myers Squibb Company, and Eli Lilly and Company.

Rheumatoid Arthritis Drugs Market Segmentation

By Drug Class Type: Based on the Drug Class Type, Global Rheumatoid Arthritis Drugs Market is segmented as, Disease-modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others.

By Route of Administration: Based on the Route of Administration, Global Rheumatoid Arthritis Drugs Market is segmented as; Oral, Parenteral.

By Sales Channel: Based on the Sales Channel, Global Rheumatoid Arthritis Drugs Market is segmented as; Prescription-based Drugs, Over-the-counter Drugs.

By Distribution Channel: Based on the Distribution Channel, Global Rheumatoid Arthritis Drugs Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.

Product Code: PHAR2406

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Rheumatoid Arthritis Drugs Market

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Rheumatoid Arthritis Drugs Market Manufacturing Base Distribution, Sales Area, Ingredients
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Rheumatoid Arthritis Drugs Market

7. Global Rheumatoid Arthritis Drugs Market, By Drug Class Type (USD Million) 2020-2033

7.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2020-2026
7.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2027-2033
7.3. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
7.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
7.5. Corticosteroids
7.6. Uric Acid Drugs
7.7. Others

8. Global Rheumatoid Arthritis Drugs Market, By Route of Administration (USD Million) 2020-2033

8.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2020-2026
8.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2027-2033
8.3. Oral
8.4. Parenteral

9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel (USD Million) 2020-2033

9.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2020-2026
9.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2027-2033
9.3. Prescription-based Drugs
9.4. Over-the-counter Drugs

10. Global Rheumatoid Arthritis Drugs Market, By Distribution Channel (USD Million) 2020-2033

10.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2020-2026
10.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2027-2033
10.3. Hospital Pharmacy
10.4. Retail Pharmacy
10.5. Online Pharmacy

11. Global Rheumatoid Arthritis Drugs Market, Forecast, 2020-2033 (USD Million)

11.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share

12. Global Rheumatoid Arthritis Drugs Market, By Region, 2020-2033 (USD Million)

12.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2020-2026)
12.2. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2027-2033)
12.3. Asia-Pacific
- 12.3.1. Australia
- 12.3.2. China
- 12.3.3. India
- 12.3.4. Japan
- 12.3.5. South Korea
- 12.3.6. Rest of Asia-Pacific
12.4. Europe
- 12.4.1. France
- 12.4.2. Germany
- 12.4.3. Italy
- 12.4.4. Spain
- 12.4.5. United Kingdom
- 12.4.6. Rest of Europe
12.5. Middle East and Africa
- 12.5.1. Kingdom of Saudi Arabia
- 12.5.2. United Arab Emirates
- 12.5.3. Qatar
- 12.5.4. South Africa
- 12.5.5. Egypt
- 12.5.6. Morocco
- 12.5.7. Nigeria
- 12.5.8. Rest of Middle-East and Africa
12.6. North America
- 12.6.1. Canada
- 12.6.2. Mexico
- 12.6.3. United States
12.7. Latin America
- 12.7.1. Argentina
- 12.7.2. Brazil
- 12.7.3. Rest of Latin America

13. Company Profile

13.1. AbbVie Inc.
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. Johnson & Johnson Innovative Medicine
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Amgen Inc.
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Pfizer Inc.
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Novartis AG
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Sanofi S.A.
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. F. Hoffmann-La Roche Ltd.
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Merck & Co., Inc.
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Bristol-Myers Squibb Company
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Eli Lilly and Company
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Others